Multiparametric MRI targeted prostate biopsy: When omit systematic biopsy?
Abstract
Introduction: To evaluate the detection rate for prostate cancer (PCa) performing multiparametric magnetic resonance imaging (mpMRI) fusion targeted biopsy (TPBx) combined only with ipsilateral systematic prostate biopsy (SPBx).
Materials and methods: From January 2023 to December 2023, 495 men with clinical suspicion of PCa underwent transperineal SPBx plus TPBx in the presence of PI-RADS score lesions ≥ 3.
Results: In 250/495 men (50.5%) a PCa was found, while 36/250 (14.4%) men had negative mpMRI. In comparison to TPBx, SPBx diagnosed a higher number of indolent PCa, 38.5 vs. 5.8%, respectively; conversely, SPBx demonstrated a higher detection rate for clinically significant PCa (97.3 vs. 85.4%) in the presence of ISUP Grade Group 2 (GG2). In details, rates were higher in the presence of GG2 (100 vs. 76%), GG3 (85.7 vs. 75.8%) and GG4 (100 vs. 86.4%) tumors. However, in GG5, both SPBx and TPBx diagnosed 100% of csPCa. Furthermore, 89.4% of the cases showed csPCa on the negative mpMRI side.
Conclusions: SPBx combined with TPBx maximized csPCa diagnosis; the use of reduced biopsy scheme limited to ipsilateral side of mpMRI lesion plus TPBx missed 11.6% csPCa. Only in the presence of PI-RADS score 5 SPBx and TPBx diagnosed both 100% of csPCa.
References
- Bergengren O, Pekala KR, Matsoukas K, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.
- Eur Urol 2023; 84:191-206.
- Pepe P, Garufi A, Priolo GD, et al. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with
- ,032 Men Who Underwent Prostate Biopsy. J Urol 2018; 200:774-778. DOI: https://doi.org/10.1016/j.juro.2018.04.061
- Roscigno M, Stabile A, Lughezzani G, et al. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients
- Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification? Clin Genitourin Cancer. 2020; 18:e698-e704. DOI: https://doi.org/10.1016/j.clgc.2020.04.006
- Pepe P, D'Urso D, Garufi A, et al. Multiparametric MRI Apparent Diffusion Coefficient (ADC) Accuracy in Diagnosing Clinically
- Significant Prostate Cancer. In Vivo 2017; 31:415-418. DOI: https://doi.org/10.21873/invivo.11075
- Salemi M, Pettinato A, Fraggetta F, et al. Expression of miR-132 and miR-212 in prostate cancer and metastatic lymph node: Case
- report and revision of the literature. Arch Ital Urol Androl 2020;92:209.
- Fiorentino V, Martini M, Dell'Aquila M, et al. Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and
- Radical Prostatectomy. Diagnostics (Basel) 2020;11:10. DOI: https://doi.org/10.3390/diagnostics11010010
- Pecci V, Troisi F, Aiello A, et al. Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in
- prostate cancer. Cancer Cell Int. 2024; 24:56.
- Pepe P, Cimino S, Garufi A, et al. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy. Scand J Urol 2017; 51:260-263. DOI: https://doi.org/10.1080/21681805.2017.1313310
- Russell JR, Siddiqui MM. Active surveillance in favorable intermediate risk prostate cancer: outstanding questions and controversies.
- Curr Opin Oncol 2022; 34:219-27.
- Pepe P, Pepe L, Pennisi M, Fraggetta F. Oncological Outcomes in Men With Favorable Intermediate Risk Prostate Cancer Enrolled in
- Active Surveillance. In Vivo 2024; 38:1300-5. DOI: https://doi.org/10.21873/invivo.13569
- Pepe P, Pennisi M. Morbidity following transperineal prostate biopsy: Our experience in 8.500 men. Arch Ital Urol Androl 2022;94:155-9. DOI: https://doi.org/10.4081/aiua.2022.2.155
- Pepe P, Candiano G, Pepe L, et al. mpMRI PI-RADS score 3 lesions diagnosed by reference vs affiliated radiological centers: Our
- experience in 950 cases. Arch Ital Urol Androl 2021; 93:139-42. DOI: https://doi.org/10.4081/aiua.2021.2.139
- Pepe P, Pepe L, Pennisi M, Fraggetta F. Which Prostate Biopsy in Men Enrolled in Active Surveillance? Experience in 110 Men Submitted to Scheduled Three-Years Transperineal Saturation Biopsy Combined With Fusion Targeted Cores. Clin Genitourin Cancer 2021;19:305-308. DOI: https://doi.org/10.1016/j.clgc.2021.01.004
- Pepe P, Garufi A, Priolo G, Pennisi M. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of
- Clinically Significant Prostate Cancer. Clin Genitourin Cancer. 2017;15:e33-e36. DOI: https://doi.org/10.1016/j.clgc.2016.07.007
- Pepe P, Aragona F. Prostate needle biopsy: 12 vs. 18 cores -- is it necessary? Urol Int 2005; 74: 19-22. DOI: https://doi.org/10.1159/000082703
- Offermann A, Hupe MC, Sailer V, et al. The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years
- after introduction and systemic review of the literature. World J Urol 2020; 38:657-62. DOI: https://doi.org/10.1007/s00345-019-02744-4
- Pepe P, Garufi A, Priolo G, Pennisi M. Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation
- of men in active surveillance? World J Urol 2016; 34:1249-53. DOI: https://doi.org/10.1007/s00345-015-1749-3
- Chang SD, Ghai S, Kim CK, et al. MRI Targeted Prostate Biopsy Techniques: AJR Expert Panel Narrative Review. AJR Am J
- Roentgenol 2021; 217:1263-81.
- Yusim I, Mazor E, Frumkin E, et al. Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI
- undergoing transperineal MRI/ultrasound fusion prostate biopsy. Prostate 2023; 83:1255-62. DOI: https://doi.org/10.1002/pros.24585
- Bourgeno HA, Jabbour T, Baudewyns A, et al. The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic
- Resonance Imaging-targeted Prostate Biopsy. Eur Urol Oncol 2024:S2588-9311(24)00031-2. Online ahead of print
- Hagens MJ, Noordzij MA, Mazel JW, et al. An Magnetic Resonance Imaging-directed Targeted-plus-perilesional Biopsy
- Approach for Prostate Cancer Diagnosis: "Less Is More". Eur Urol Open Sci 2022; 43:68-73. DOI: https://doi.org/10.1016/j.euros.2022.07.006
- Deniffel D, Perlis N, Ghai S, et al. Prostate biopsy in the era of MRItargeting: towards a judicious use of additional systematic biopsy. Eur Radiol 2022; 32:7544-54. DOI: https://doi.org/10.1007/s00330-022-08822-3
- Sawhney V, Huang R, Huang WC, et al. Predictors of Contralateral Disease in Men with Unilateral Lesions on Multiparametric MRI.
- Urology. 2024:S0090-4295(24)00564-8. Online ahead of print
- Phelps TE, Yilmaz EC, Harmon SA, et al. Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with
- unilateral mpMRI-visible lesions. Abdom Radiol (NY) 2023;48:1079-89.
- Hou Y, Jiang KW, Zhang J, et al. A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI. Prostate
- Cancer Prostatic Dis. 2022; 25:727-34. DOI: https://doi.org/10.1038/s41391-021-00489-z
- Avolio PP, Lughezzani G, Anidjar M, et al. The diagnostic accuracy of micro-ultrasound for prostate cancer diagnosis: a review. World J Urol 2023; 41:3267-76. DOI: https://doi.org/10.1007/s00345-023-04521-w
- Pepe P, Pepe L, Tamburo M, et al. Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer. Arch Ital Urol Androl 2022; 94:274-77. DOI: https://doi.org/10.4081/aiua.2022.3.274
- Pepe P, Pennisi M. Targeted Biopsy in Men High Risk for Prostate Cancer: 68Ga-PSMA PET/CT Versus mpMRI. Clin Genitourin
- Cancer 2023; 21:639-42. DOI: https://doi.org/10.1016/j.clgc.2023.06.007
- Pepe P, Pepe L, Cosentino S, et al. Detection Rate of 68Ga-PSMA PET/CT vs. mpMRI Targeted Biopsy for Clinically Significant Prostate
- Cancer. Anticancer Res 2022; 42:3011-15. DOI: https://doi.org/10.21873/anticanres.15785
- Pepe P, Roscigno M, Pepe L, et al. Could 68Ga-PSMA PET/CT Evaluation Reduce the Number of Scheduled Prostate Biopsies in Men
- Enrolled in Active Surveillance Protocols? J Clin Med. 2022;11:3473. DOI: https://doi.org/10.3390/jcm11123473
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2024 the Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.